サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1293760

短腸症候群市場：薬剤クラス別、流通チャネル別-2023-2030年の世界予測

Short Bowel Syndrome Market by Drug Class, Distribution Channel - Russia Ukraine Conflict and High Inflation - Global Forecast 2023-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 182 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
短腸症候群市場：薬剤クラス別、流通チャネル別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 182 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

短腸症候群の世界市場は、2023年に8億1,823万米ドル、CAGR18.95％で大きく成長し、2030年には27億8,872万米ドルに達すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の短腸症候群市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展：有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化：新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向：ロシア・ウクライナ紛争、高インフレに関する包括的な理解を提供します。

5.競合の評価と情報：主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション：将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします：

1.短腸症候群の世界市場規模および予測は？

2.予測期間中、世界の短腸症候群市場を形成するCOVID-19の阻害要因と影響は？

3.短腸症候群の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は？

4.短腸症候群の世界市場における競争戦略は？

5.短腸症候群の世界市場における技術動向と規制の枠組みは？

6.短腸症候群の世界市場における主要ベンダーの市場シェアは？

7.短腸症候群の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 短腸症候群と啓発プログラムの普及率の増加
      • 効果的な治療法の発売に向けた取り組みの強化
    • 抑制要因
      • 承認された治療選択肢の欠如と薬剤に伴う有害な合併症
    • 機会
      • 短腸症候群医薬品の開発は初期段階にあります
      • 官民パートナーシップにより製薬会社が短腸症候群向けの新しい希少疾病用医薬品の開発を奨励
    • 課題
      • 限定的な初期診断と高度なオプションの利用可能性
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 短腸症候群市場薬物クラス別

  • GLP-2
  • グルタミン
  • 成長ホルモン

第7章 短腸症候群市場：流通チャネル別

  • 病院薬局
  • オンライン販売
  • 小売薬局

第8章 南北アメリカの短腸症候群市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の短腸症候群市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの短腸症候群市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ分析：主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. SHORT BOWEL SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. SHORT BOWEL SYNDROME MARKET SIZE, 2022 VS 2030
  • FIGURE 3. SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
  • FIGURE 5. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
  • FIGURE 6. SHORT BOWEL SYNDROME MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. SHORT BOWEL SYNDROME MARKET DYNAMICS
  • FIGURE 8. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. SHORT BOWEL SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. SHORT BOWEL SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 5. SHORT BOWEL SYNDROME MARKET SIZE, BY GLP-2, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. SHORT BOWEL SYNDROME MARKET SIZE, BY GLUTAMINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. SHORT BOWEL SYNDROME MARKET SIZE, BY GROWTH HORMONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 9. SHORT BOWEL SYNDROME MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. SHORT BOWEL SYNDROME MARKET SIZE, BY ONLINE SALES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. SHORT BOWEL SYNDROME MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 15. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 17. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 21. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 23. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 29. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 33. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 51. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 56. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 58. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 60. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 62. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 64. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 66. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 68. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 70. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 72. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 74. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 76. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 80. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 82. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 86. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 88. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 92. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM SHORT BOWEL SYNDROME MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 98. SHORT BOWEL SYNDROME MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 99. SHORT BOWEL SYNDROME MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 100. SHORT BOWEL SYNDROME MARKET LICENSE & PRICING
目次
Product Code: MRR-0309FBC5113F

The Global Short Bowel Syndrome Market is forecasted to grow significantly, with a projected USD 818.23 million in 2023 at a CAGR of 18.95% and expected to reach a staggering USD 2,788.72 million by 2030.

The the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Short Bowel Syndrome Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Short Bowel Syndrome Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Drug Class, market is studied across GLP-2, Glutamine, and Growth Hormone. The Glutamine commanded largest market share of 39.26% in 2022, followed by GLP-2.

Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Sales, and Retail Pharmacies. The Retail Pharmacies commanded largest market share of 52.51% in 2022, followed by Hospital Pharmacies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa commanded largest market share of 35.38% in 2022, followed by Americas.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Short Bowel Syndrome Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Short Bowel Syndrome Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Short Bowel Syndrome Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Short Bowel Syndrome Market?

4. What is the competitive strategic window for opportunities in the Global Short Bowel Syndrome Market?

5. What are the technology trends and regulatory frameworks in the Global Short Bowel Syndrome Market?

6. What is the market share of the leading vendors in the Global Short Bowel Syndrome Market?

7. What modes and strategic moves are considered suitable for entering the Global Short Bowel Syndrome Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Short Bowel Syndrome Market, by Drug Class, 2022 vs 2030
  • 4.3. Short Bowel Syndrome Market, by Distribution Channel, 2022 vs 2030
  • 4.4. Short Bowel Syndrome Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increased Prevalence of Short Bowel Syndrome and Awareness Programs
      • 5.1.1.2. Rising Efforts in the Launch of Effective Treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of Approved Treatment Options and Associated Adverse Complications with Drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Development of Short Bowel Syndrome Drugs is at a Nascent Stage
      • 5.1.3.2. Public-Private Partnerships are Encouraging Pharmaceutical Companies to Develop New Orphan Drugs for Short Bowel Syndrome
    • 5.1.4. Challenges
      • 5.1.4.1. Limited Initial Diagnostic and Availability of Advanced Option
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Short Bowel Syndrome Market, by Drug Class

  • 6.1. Introduction
  • 6.2. GLP-2
  • 6.3. Glutamine
  • 6.4. Growth Hormone

7. Short Bowel Syndrome Market, by Distribution Channel

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Online Sales
  • 7.4. Retail Pharmacies

8. Americas Short Bowel Syndrome Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Short Bowel Syndrome Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Short Bowel Syndrome Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing

1. 9 Meters Biopharma, Inc.

2. Adocia SAS

3. Ardelyx Inc.

4. AstraZeneca PLC

5. Emmaus Life Sciences, Inc.

6. Merck KGaA

7. Nestle S.A.

8. Novartis International AG

9. OPKO Health, Inc.

10. Oxthera AB

11. Pfizer Inc.

12. PhaseBio Pharmaceuticals Inc.

13. Sancilio and Company, Inc.

14. Swedish Orphan Biovitrum AB

15. Takeda Pharmaceutical Company Limited

16. Teva Pharmaceutical Industries Ltd.

17. VectivBio AG

18. Viatris Inc.

19. Zealand Pharma A/S